esoteric and routine testing demonstrated solid year - over - year growth for the quarter.
in the third quarter , we delivered strong results.
revenue totaled $ 4.1 billion , adjusted earnings per share reached $ 6.82 , and free cash flow was $ 650 million.
at the same time , we 've remained focused on helping the world through the pandemic.
glenn will cover those in more detail in a few minutes.
capital expenditures totaled $ 118 million or 2.9 % of revenue compared to $ 77 million or 2 % of revenue last year.
the base business for both diagnostics and drug development performed well with 10 % and 22 % growth , respectively.
we serve as a trusted source of health information that helps customers advance healthcare and guide medical decisions.
labcorp continues to support the fight against the pandemic in every way possible through both our diagnostic and our drug development capabilities.
now i 'd like to turn to our ongoing role in the pandemic response.
the business also saw decentralized trials increasing by more than 50 % versus prior year.
we saw consistent recovery across both businesses.
in diagnostics , we experienced broad geographic recovery in our base business and across our testing portfolio.
drug development continues to recover with nearly 85 % of sites now open.
at labcorp , we continue to leverage innovation , science and technology to accelerate our strategy as we work to improve health and improve lives around the world.
the trailing 12 - month net book - to - bill for drug development remains strong at 1.34.
